+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 72 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness of delgocitinib cream 20 mgg applied twice daily compared to a non-active cream vehicle in treating adults with mild to severe palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This phase 2a, double-blind study aims to provide proof-of-concept evidence over a 16-week treatment period. Participants will be randomly assigned to one of two groups one group will apply delgocitinib cream twice daily, and the other will apply a matching vehicle cream twice daily for 16 weeks. The study includes approximately 9 visits over about 18 weeks in total, covering treatment and follow-up periods. Throughout the trial, participants will attend scheduled visits for assessments including skin evaluations, photography confirmation of PPP, and various symptom and quality of life measures. Researchers will monitor improvements using the PPP Area and Severity Index PPPASI and Physician Global Assessment PGA, as well as track adverse events and changes in symptoms like itch and pain. The main outcome is the number of participants achieving at least a 75% improvement in PPPASI score after 16 weeks of treatment.

Age: 18Years +All GendersPhase 2
40 locations
P

Actively Recruiting

Researchers are evaluating the effects of an investigational medicine called PGN-EDODM1 to understand how safe and tolerable multiple doses are for adults with myotonic dystrophy type 1 DM1. This phase 2 study compares PGN-EDODM1 to a placebo to assess its safety and tolerability in people with this condition. Participants will be randomly assigned to receive either PGN-EDODM1 or a placebo. The treatment is given by intravenous infusion once every 4 weeks for a total of 12 weeks. Those in the PGN-EDODM1 group will receive ascending doses, while the placebo group will receive saline infusions on the same schedule. During the study, participants will be monitored for safety by tracking adverse events from the start through Day 112. Researchers will measure drug levels in the blood, changes in muscle tissue, myotonia severity, hand grip strength, and mobility using specific tests. The total participation lasts through about 16 weeks, including treatment and follow-up assessments.

Age: 16Years - 65YearsAll GendersPhase 2
12 locations
S

Actively Recruiting

Researchers are studying the safety and effectiveness of FLT201, a gene therapy, in adults with Gaucher disease Type 1 who have been on stable enzyme replacement or substrate reduction therapy for at least two years. This Phase 3 study aims to confirm how well FLT201 works and its safety after participants stop their current therapies. Participants will receive a single intravenous infusion of FLT201, which is an advanced gene therapy made from a modified virus vector carrying genetic material. The study is non-randomized and conducted at multiple centers, focusing on this one group receiving the investigational treatment. Throughout the study, participants will be monitored for response to FLT201 over a year to evaluate its effectiveness. Researchers will assess safety and track health outcomes, with the overall study lasting several years. This includes follow-up visits and evaluations to understand long-term impacts of the gene therapy.

Age: 18Years +All GendersPhase 3
32 locations
G

Actively Recruiting

This research is a global, multicenter, prospective observational registry studying patients with Pompe disease, including both late-onset LOPD and infantile-onset IOPD forms. It enrolls both untreated patients and those receiving approved therapies to better understand the long-term safety, real-world effectiveness, and quality of life impacts of treatments for Pompe disease. The study also aims to describe the natural history of untreated Pompe disease. Participants include groups receiving different enzyme replacement therapies such as Cipaglucosidase alfa with Miglustat, other approved ERTs like Alglucosidase alfa or Avalglucosidase alfa, as well as untreated individuals who are not on any medical therapy for Pompe disease. No experimental treatments are given as this is an observational study tracking real-world treatment use and outcomes. During the study, participant data on adverse events, treatment effectiveness, quality of life, and patient-reported outcomes will be collected over a period of at least five years. Researchers will monitor safety through the frequency of adverse events and serious adverse events. Participants health and treatment impacts will be regularly evaluated to provide long-term insights into Pompe disease management and outcomes.

All AgesAll Genders
41 locations
O

Actively Recruiting

Researchers are conducting a long-term observational study to understand the natural history, symptoms, and progression of fucosidosis, a rare disease without any approved treatments. This study aims to collect detailed information from individuals diagnosed with fucosidosis to better characterize the disease and inform future research and treatment development. The study is sponsored by JCR Pharmaceuticals Co., Ltd. and includes both retrospective and prospective components. The study has two parts Part A involves collecting past medical data from up to 57 participants, while Part B includes ongoing prospective data collection from up to 31 participants, many of whom may have participated in Part A. No experimental treatments are given participants receive only their usual medical care during the study. Participants will be observed over time to evaluate disease progression, with data collected from medical records and regular follow-up visits. The primary goal is to assess how fucosidosis develops in untreated individuals over up to four years. Information collected includes symptoms, treatment history, and clinical assessments to help researchers understand the disease course and support future study design. Participation may last several years depending on individual involvement in prospective data collection.

All AgesAll Genders
16 locations
L

Actively Recruiting

This research aims to evaluate the long-term safety and efficacy of APG777 in adults with moderate-to-severe atopic dermatitis who have already completed treatment in a prior APG777 study. The study is a multicenter, double-blind, phase 2 extension designed for participants who, according to the investigator, could benefit from continued APG777 treatment. The study consists of three periods a Screening Visit coinciding with the last visit of the parent studys Maintenance Period an Extended Treatment Period where participants maintain their APG777 dose from the previous study or receive open-label APG777 if they did not meet certain response criteria and a Post-treatment Follow-up Period. Participants receive APG777 as subcutaneous injections every 12 or 24 weeks, depending on their previous dosing regimen or study arm assignment. During the study, participants will have assessments for safety and efficacy, including monitoring treatment-emergent adverse events for up to 3 years. Researchers will also track improvements in eczema severity, itch symptoms, use of rescue therapy, and serum drug concentrations over an average of 2 years during the Extended Treatment Period. Participation may last up to 3 years, including follow-up to observe long-term outcomes.

Age: 18Years +All GendersPhase 2
80 locations
O

Actively Recruiting

Researchers are conducting a large, multi-country observational study to assess the safety and effectiveness of pegunigalsidase alfa Elfabrio in patients with Fabry disease. This study includes patients who are currently treated with pegunigalsidase alfa in routine care and gathers data both retrospectively and prospectively. The study considers different patient groups such as those with Fabry-related heart disease, treatment-nave patients, and those transitioning from an earlier open-label extension study. The treatment being observed is pegunigalsidase alfa, administered through intravenous infusion as part of routine clinical care. Participants are grouped into cohorts based on their disease status and treatment history, including a cardiac cohort with Fabry-related heart involvement, a nave cohort who have not received prior Fabry treatment, and a long-term cohort of patients continuing from a previous clinical study. The study does not intervene in treatment but observes patients receiving this drug in real-world settings. Participants will be followed for up to four years, during which researchers will collect various clinical measurements such as kidney function estimated glomerular filtration rate, plasma lysoGb3 levels, heart structure and function via left ventricular mass index and cardiac biomarkers, and overall safety assessments. Data will be collected through routine clinical visits, imaging studies, and patient-reported outcomes. The study aims to provide comprehensive long-term information on the effects and safety of pegunigalsidase alfa in everyday clinical practice.

Age: 18Years +All Genders
10 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with lichen planopilaris, a condition affecting the scalp. This Phase 23 trial aims to understand how well this medication works compared to a placebo in treating active and symptomatic lichen planopilaris. The study is sponsored by Priovant Therapeutics, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants are randomly assigned to receive either oral brepocitinib or a placebo. The study is conducted in parallel groups, with neither the participants nor the researchers knowing who receives the active drug or placebo. The treatment period lasts 24 weeks, during which the participants take the assigned oral medication. The main goal is to measure improvement in the Investigator Global Assessment IGA score by Week 24. Throughout the study, participants will be regularly monitored for safety and symptom changes. Researchers will assess the proportion of participants who achieve significant improvement in their IGA scores at Week 24 and track changes in symptom severity using a numerical rating scale. The total study duration extends until July 2029, allowing for thorough evaluation of treatment effects and safety over time.

Age: 18Years +All GendersPhase 2Phase 3
61 locations
F

Actively Recruiting

Healthy Volunteer

Researchers are evaluating MTX325 as a potential disease-modifying treatment for Parkinsons Disease PD in this multi-part Phase 1 trial. The study includes healthy volunteers and patients with mild to moderate and early-stage PD, aiming to assess safety, tolerability, pharmacokinetics, brain biodistribution, and the effects of food on the drug. Parts 1 to 4, involving single and multiple ascending doses in healthy adults including elderly participants, are complete, with Part 5 focusing on multiple doses in PD patients currently ongoing. Participants receive oral capsules of MTX325 at various doses or matching placebo capsules depending on the study part. The trial includes a PET biodistribution study with radiolabeled MTX325 in healthy volunteers. Parts 1 through 4 evaluated single ascending doses, multiple ascending doses, elderly cohorts, and PET biodistribution, while Part 5 involves multiple dosing in PD patients. The study uses a randomized, parallel design without masking. Participants undergo screening including MRI and PET imaging, laboratory testing, ECG, and cognitive assessments before dosing. Safety and tolerability are monitored up to 28 days post-dose. The study involves repeated visits for assessments and dosing, with adherence to scheduled visits and protocols required. Researchers measure adverse events, brain drug distribution, and pharmacokinetics to evaluate MTX325s potential as a PD treatment. The total study duration varies by part, with ongoing follow-up to assess safety and drug effects.

Age: 18Years - 75YearsAll GendersPhase 1
18 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations

1-10 of 72

1